정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1213 | Recruiting | Impact of COVID-19 Pandemic and Social Distancing on Mental Health of Chronic Inflammatory Rheumatism Affected Patients | Mental Disorder | Behavioral: Questionnaire Biological: blood sample and salivary sample |
Not Applicable | University Hospital, Bordeaux, Societe Francaise de Rhumatologie | OTHER | 318 | All | 18 Years | CHU de Bordeaux - service de rhumatologie, Bordeaux, France AP-HP - Hopital Henri Mondor - service de rhumatologie, Creteil, France CHRU de Lille - Service de rhumatologie, Lille, France CHU de Montpellier - service de rhumatologie, Montpellier, France AP-HP - Hopital Cochin - service de rhumatologie, Paris, France CHU de Saint-Etienne - service de rhumatologie, Saint-Etienne, France CHU de Toulouse - service de rhumatologie, Toulouse, France |
| 1212 | Not yet recruiting | Impact of GSE and Xylitol (Xlear) on COVID-19 Symptoms and Time to PCR Negativisation in COVID-19 Patients | Covid19 | Other: GSE and Xylitol Drug: Control Placebo |
Phase 3 | Larkin Community Hospital | OTHER | 250 | All | 18 Years ~ 90 Years | Larkin Community Hospital Palm Springs Campus, Miami, Florida, United States Larkin Community Hospital, Miami, Florida, United States |
| 1211 | Recruiting | Impact of Immunosuppression Adjustment on COVID-19 Vaccination Response in Kidney Transplant Recipients | Vaccine Response Impaired | Drug: Reduction in antimetabolite immunosuppression | Phase 4 | University of California, Davis, CareDx | OTHER | 50 | All | 18 Years | University of California, Davis, Sacramento, California, United States |
| 1210 | Recruiting | Impact of Intravenous Lidocaine on Clinical Outcomes of Patients With ARDS During COVID-19 Pandemia | Corona Virus Infection | Drug: Lidocaine 2% Drug: Control |
Phase 3 | University Hospital, Strasbourg, France | OTHER | 100 | All | 18 Years | University Hospital of Hautepierre, Strasbourg, Bas-Rhin, France |
| 1209 | Recruiting | Impact of PCSK9 Inhibition on Clinical Outcome in Patients During the Inflammatory Stage of the COVID-19 | Sars-CoV-2 Infection | Drug: Evolocumab Drug: Saline solution |
Phase 3 | Collegium Medicum w Bydgoszczy | OTHER | 60 | All | 18 Years | Antoni Jurasz University Hospital No. 1, Bydgoszcz, Poland |
| 1208 | Completed | Impact of Steroids on Inflammatory Response in Covid-19 | Covid19 | Drug: Dexamethasone Drug: Methylprednisolone |
Phase 3 | Assiut University | OTHER | 60 | All | 18 Years | Assiut university hospital, Assiut, Assuit, Egypt |
| 1207 | Recruiting | Impact of the Immune System on Response to Anti-Coronavirus Disease 19 (COVID-19) Vaccine in Allogeneic Stem Cell Recipients (Covid Vaccin Allo) | Hematopoietic Neoplasms | Drug: anti-COVID19 mRNA-based vaccine (BNT162b2, Comirnaty®, commercialized by Pfizer) | Phase 3 | University of Liege, Pfizer | OTHER | 50 | All | 18 Years ~ 100 Years | CHU Liege, Domaine du Sart-Tilman, Liege, Belgium |